Market Mover: Spruce (SPRB) Up at Midday June 21

Equities Staff  |

Today Spruce Biosciences Inc (NASDAQ: SPRB) is trading 6.91% up.

The latest price, as of 12:05:36 est, was $1.63. Spruce has moved $0.105 so far today.

42,634 shares have exchanged hands.

As of the previous close, Spruce has moved YTD 65.92%. The company anticipates its next earnings on 2022-08-10.

For technical charts, analysis, and more on Spruce visit the company profile.

About Spruce Biosciences Inc

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States).

To get more information on Spruce Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Spruce Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content